AFT Pharmaceuticals

Overview
Price performance
Financials
Research
Thematics

AFT Pharmaceuticals is a specialty pharmaceutical company that operates primarily in Australasia but has product distribution agreements across the globe. The company’s product portfolio includes prescription and over-the-counter (OTC) drugs to treat a range of conditions and a proprietary nebuliser.

AFT Pharmaceuticals is a multi-product company targeting pharmacy prescription, OTC and hospital markets. Data for Maxigesic offer it a competitive advantage in a fragmented industry.

Latest Insights

Healthcare |
Flash note

02.05.24

AFT Pharmaceuticals — Maxigesic IV’s Brazil entry, a foray into LATAM

Healthcare |
Flash note

29.04.24

AFT Pharmaceuticals — Expanded R&D pipeline to fuel LT growth

Healthcare |
Flash note

05.03.24

AFT Pharmaceuticals — Poised for international market expansion

Healthcare |
Update

19.02.24

AFT Pharmaceuticals — US milestone triggers upside and guidance bump

Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Analyst

Jyoti Prakash

Analyst, Healthcare

Arron Aatkar

Associate analyst

Key Management

David Flacks

Chairman
Dr Hartley Atkinson

CEO
Malcolm Tubby

Chief Financial Officer
Michael Weinmann

Member of the Board of Directors
Nathan D. Hukill

Member of the Board of Directors

Balance Sheet

Forecast net debt (NZ$m)

25.6

Forecast gearing ratio (%)

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	(3.5)	(19.8)	(11.0)
Relative	(1.7)	(18.6)	(6.8)
52 week high/low	3.9/2.8

Financials

AFT continues to expand its Maxigesic IV footprint with the announcement of a licensing agreement in Brazil, the largest pharma market in South America and tenth largest market globally. The deal signed with Halex Istar, a leading manufacturer of injectables in the country, provides a strong foundation for further extension into the Latin American and global markets, an overarching long-term goal for AFT. Maxigesic IV is a higher-strength version of AFT’s proprietary paracetamol plus ibuprofen formulation targeting post-surgical pain relief in the hospital setting. It is currently available in 36 countries, including the US, with the recent launch by Hikma, its distribution partner.